Detecting Metastatic Prostate Cancer with Prostate-Specific Membrane Antigen PET-CT

PSMA PET-CT had greater sensitivity and specificity than conventional imaging for detecting pelvic nodal or distant metastases in men with high-risk prostate cancer.

The limitations in sensitivity and specificity of conventional imaging using computed tomography (CT) and bone scans in staging patients with locally advanced prostate cancer are well defined. To determine whether prostate-specific membrane antigen (PSMA) positron emission tomography (PET)-CT imaging is more accurate than conventional imaging in this setting, investigators in Australia conducted a prospective, multicenter, randomized, crossover, phase III trial of 295 assessable men (median age, 69) with high-risk, localized prostate cancer (defined as International Society of Uropathology grade 3–5, prostate-specific antigen [PSA] concentration of ≥20 ng/mL, or clinical stage ≥T3).

Patients were randomized to undergo PSMA PET-CT imaging or …

Reviewing Author

Robert Dreicer, MD, MS, MACP, FASCO

Disclosures

Consultant/Advisory BoardAstellas; Aveo; Bayer; Gilead; Merck; Pfizer; Propella; Macrogenics

Editorial BoardsCurrent Urology Reports

Robert Dreicer, MD, MS, MACP, FASCO

Disclosures

Consultant/Advisory BoardAstellas; Aveo; Bayer; Gilead; Merck; Pfizer; Propella; Macrogenics

Editorial BoardsCurrent Urology Reports

Detecting Metastatic Prostate Cancer with Prostate-Specific Membrane Antigen PET-CT

Topics

Reviewing Author